Actinium Pharmaceuticals, Inc. (Delaware) (ATNM): Price and Financial Metrics

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM): $7.31

0.24 (-3.18%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ATNM to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#139 of 347

in industry

ATNM Price/Volume Stats

Current price $7.31 52-week high $10.24
Prev. close $7.55 52-week low $4.00
Day low $7.31 Volume 418,900
Day high $7.70 Avg. volume 304,656
50-day MA $8.20 Dividend yield N/A
200-day MA $6.57 Market Cap 217.71M

ATNM Stock Price Chart Interactive Chart >


Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) Company Bio


Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company’s targeted radio immunotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting Actinium-225 and Bismuth-213, and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The company was founded in 2000 and is based in New York City, New York.


ATNM Latest News Stream


Event/Time News Detail
Loading, please wait...

ATNM Latest Social Stream


Loading social stream, please wait...

View Full ATNM Social Stream

Latest ATNM News From Around the Web

Below are the latest news stories about ACTINIUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ATNM as an investment opportunity.

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 65th Annual American Society of Hematology Meeting & Exposition (ASH). The oral presentation highlighted significantly improved survival in patients with a TP53 mutation receiving Iomab-B.

Yahoo | December 11, 2023

Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) detailing results from the Phase 3 SIERRA trial of Iomab-B and Phase 1 trial of Actimab-A in combination with Venetoclax in patients with relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B and Actimab-A are the only two clinical

Yahoo | December 11, 2023

Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023. These include an oral presentation and two poster presentations detailing results from the completed and positive Phas

Yahoo | December 8, 2023

Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced data was presented at Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting on Saturday, November 4, 2023, further supporting Actimab-A, the Company's clinical stage targeted radiotherapeutic comprised of the CD33 targeting antibody lintuzumab and the Actinium-225 (Ac-225) alpha-particle emitting payload.

Yahoo | November 6, 2023

Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany.

Yahoo | November 2, 2023

Read More 'ATNM' Stories Here

ATNM Price Returns

1-mo -13.18%
3-mo -20.54%
6-mo N/A
1-year -2.66%
3-year -6.04%
5-year -6.39%
YTD 43.90%
2023 -52.30%
2022 77.20%
2021 -22.95%
2020 19.43%
2019 -44.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!